Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

@article{Tipton2015AntigenicML,
  title={Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.},
  author={Thomas R. W. Tipton and Ali Roghanian and Robert J Oldham and Matthew J. Carter and Kerry Cox and C. Ian Mockridge and Ruth R. French and L N Dahal and Patrick J Duriez and Philip G Hargreaves and Mark S Cragg and Stephen A Beers},
  journal={Blood},
  year={2015},
  volume={125 12},
  pages={1901-9}
}
Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab, a type II mAb, lacks the ability to redistribute into lipid rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC). We previously showed that type I mAbs such as rituximab have a propensity to undergo enhanced antigenic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

The biological activity of human CD20 monoclonal antibodies is linked to unique 1908 TIPTON et al BLOOD

  • JL Teeling, WJ Mackus, LJ Wiegman
  • MARCH 2015 x VOLUME 125,
  • 2017
1 Excerpt

Similar Papers

Loading similar papers…